The online version of this article (doi:10.1186/1471-2288-13-152) contains supplementary material, which is available to authorized users.
Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, we describe the use of the restricted mean survival time as a possible alternative tool in the design and analysis of these trials.
The restricted mean is a measure of average survival from time 0 to a specified time point, and may be estimated as the area under the survival curve up to that point. We consider the design of such trials according to a wide range of possible survival distributions in the control and research arm(s). The distributions are conveniently defined as piecewise exponential distributions and can be specified through piecewise constant hazards and time-fixed or time-dependent hazard ratios. Such designs can embody proportional or non-proportional hazards of the treatment effect.
We demonstrate the use of restricted mean survival time and a test of the difference in restricted means as an alternative measure of treatment effect. We support the approach through the results of simulation studies and in real examples from several cancer trials. We illustrate the required sample size under proportional and non-proportional hazards, also the significance level and power of the proposed test. Values are compared with those from the standard approach which utilizes the logrank test.
We conclude that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial. Restricted mean survival time may provide a practical way forward and deserves greater attention.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957. 10.1056/NEJMoa0810699. CrossRefPubMed
Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011, 29 (S): LBA5006-
Barthel FMS, Royston P, Babiker A: A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. Stat J. 2005, 5: 123-129.
Rosner B: Fundamentals of Biostatistics. 2006, Belmont, Ca: Duxbury Press
Royston P, Lambert PC: Flexible parametric survival analysis using Stata beyond the Cox model. 2011, College Station, Tx: Stata Press
Lambert PC, Royston P: Further development of flexible parametric models for survival analysis. Stat J. 2009, 9: 265-290.
Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RTD, Mardiak J, Hussain T, Sylvester R, Parmar MKB, Royston P, Mulders PFA: Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04 / EORTC GU 30012): an open-label randomised trial. Lancet. 2010, 375: 641-648. 10.1016/S0140-6736(09)61921-8. CrossRefPubMedPubMedCentral
International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party: Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999, 354: 533-540. CrossRef
Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359: 1727-1733. CrossRef
Gigerenzer G: Reckoning with risk. 2002, London, UK: Allen Lane
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Mahesh KB Parmar
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
e.Med Kampagnen-Visual, Mail Icon II